Waystar Holding Corp Dossier - Source-backed chat

Waystar Holding Corp

WAYNASDAQ

SectorHealth Care

IndustryHealth Information Services

Beta (adjusted)0.44

Intrinsic Value $35.96median of 6 methods · middle span $25-$72based on filings through 30 Jun 2026

Market Price $25.34Price as of 30 Sep 2026

UndervaluedIntrinsic value is 42% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $4.9B

Enterprise Value $6.3B

Shares Outstanding 198.6M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Waystar Holding Corp. (WAY) presents a compelling investment opportunity in the healthcare revenue cycle management (RCM) software space. The company's stock has experienced significant technical downward pressure, trading over 50% below its 52-week high, primarily driven by private equity block sales rather than deteriorating business fundamentals. Operationally, Waystar continues to deliver robust performance, highlighted by 22% year-over-year revenue growth in Q1 2026, stable adjusted EBITDA margins of 43%, and strong cash generation. The launch of its AI-powered AltitudeAI suite and the successful integration of Iodine Software position Waystar to capture a substantial share of the $100B+ addressable healthcare billing market. With a newly authorized $200 million share repurchase program and overwhelming buy ratings from Wall Street analysts, the stock is highly attractive for long-term investors as the PE overhang clears.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets23 analysts · as of 18 Aug 2026

Low · most bearish analyst$27.00

Mean target$33.17

High · most bullish analyst$44.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case assumes a deceleration in organic revenue growth to high single digits due to prolonged integration challenges with Iodine Software, slower-than-expected client onboarding, or intense competitive pressure in the RCM space. Continued block sales by PE sponsors keep the stock price depressed, while adjusted EBITDA margins contract toward 40% due to increased R&D and sales investments.

Base CaseCentral scenario

The base case assumes Waystar successfully executes its organic growth strategy, driven by the adoption of its AI-powered AltitudeAI suite and steady cross-selling of Iodine Software solutions. Revenue grows in line with full-year 2026 guidance of $1.274B to $1.294B, and adjusted EBITDA margins remain stable at 42-43%. Private equity block sales gradually subside, allowing the stock to re-rate toward its historical and peer multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong financial performance with 22% YoY revenue growth and 43% adjusted EBITDA margins in Q1 2026.
High revenue visibility supported by a recurring, usage-based subscription model with a 111% Net Revenue Retention (NRR) rate.
Leadership in healthcare AI transformation through the AltitudeAI suite, driving approximately 40% of new bookings.
Significant valuation discount relative to peers, with the current stock price depressed by temporary private equity selling pressure rather than business fundamentals.
Strong capital allocation flexibility, supported by robust free cash flow and a newly authorized $200 million share repurchase program.

Key Investment Risks

Ongoing technical pressure and stock price volatility from remaining private equity ownership (estimated at ~33%).
Execution and integration risks associated with the Iodine Software acquisition and achieving projected synergies.
Potential normalization or deceleration of Net Revenue Retention (NRR) rates as the client base scales.
Intense competition in the healthcare RCM software market from both legacy players and emerging technology vendors.

Thesis Invalidation Triggers

A significant drop in the Net Revenue Retention (NRR) rate below 105%.
A material contraction in the adjusted EBITDA margin below 40%.
Failure to achieve the guided full-year 2026 revenue range of $1.274B to $1.294B.
Prolonged integration delays or customer attrition related to the Iodine Software platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.